May 01, 2024

Berry Corp (BRY) Loses Energy on Its Q1 Earnings as Stock Trades Down

The energy exploration and PRISM Oil and Gas Index company, Berry Corporation (BRY) announced its Q1 earnings today that disappointed on estimates. Q1 EPS was $0.14 vs FactSet $0.18 and revenues had a steeper miss at $131.1M vs FactSet $182.7M driven by lower oil prices and decrease in volumes. Despite the miss, the company anticipates… [Read More]
Estee lauder storefront
May 01, 2024

Market Overview: Stocks Decline Amid Economic Uncertainty and Fed Rate Decisions

Economic Indicators: US factory activity contracted with input prices rising at the fastest pace since 2022. Job openings have reached a three-year low, indicating a cooling labor market. Federal Reserve Stance: Amidst weaker-than-expected economic data, traders anticipate the Fed to maintain its current rate, delaying any cuts. The Fed is likely to hold rates steady… [Read More]
May 01, 2024

Lipocine Completes Dosing in Pivotal Postpartum Depression Study

Shares in Lipocine Inc. (Nasdaq: LPCN) rose slightly to reach $4.63 after the company announced that it had completed dosing of subjects in its pivotal clinical study of LPCN 1154 (oral brexanolone) as a treatment for postpartum depression (PPD). Lipocine’s pharmacokinetic (PK) study designed to support a New Drug Application (NDA) for LPCN 1154. PPD… [Read More]
May 01, 2024

Addex Therapeutics Stumbles on Missed Primary Endpoint in Phase 2 Epilepsy Study

Shares in biopharmaceutical company, Addex Therapeutics (Nasdaq: ADXN), dropped on Monday after the company announced topline data from its Phase 2 study of ADX71149 in the treatment of epilepsy. The company’s share price closed up +1.46% on Tuesday after two choppy trading sessions. ADX71149, which has been found to be safe and well-tolerated, is being… [Read More]
May 01, 2024

Scientific Paper Makes Case for ZyVersa’s Inflammasome ASC Inhibitor; Shares Jump 36%

Specialty biopharmaceutical company, ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) has announced that acclaimed inflammasome researchers from the University of Miami Miller School of Medicine and inventors of Inflammasome ASC Inhibitor IC 100, have published a scientific paper in the peer-reviewed journal, Frontiers in Molecular Neuroscience, highlighting the relationship between inflammasome-mediated inflammation in Alzheimer’s disease and heart… [Read More]